SURPASS-CVOT is unique, in that it compares the dual incretin agonist with a GLP-1 RA that has been shown to have cardiovascular benefit in people with type 2 diabetes and high risk ASCVD
The global signal, ALFF, and FCD were tested in GraphPad (version 9.5.1 GraphPad Software, LLC) using the built-in ROUT method to find outliers
Check it out here: To view or add a comment, sign in For Chronic Lifestyle Diseases: Diabetes, High BP, PCOD, Fatty Liver, Obesity, Hypothyroidism, and more -- People try 3 things (but none of them work on the root cause of the disease): 1) Medication - which only suppresses symptoms
GLP-1s may not be suitable for everyone
She has a magical touch, and my skin has never looked better
Current FDA-Approved GLP-1 Pricing Context: Cash-pay costs for GLP-1 weight management drugs can be high without coverage, and coverage varies widely by plan